| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/11/2009 | EP2033629A1 Solid pharmaceutical composition comprising valsartan |
| 03/11/2009 | EP2033620A1 Formulation of natural triterpenes and biophenols obtained from the genus olea in liposomes |
| 03/11/2009 | EP2033616A1 Method of producing nanoparticle dispersion of medicinal component |
| 03/11/2009 | EP2033529A2 Synbiotic composition for infants |
| 03/11/2009 | EP2033526A1 Nutritional products comprising pomegranate extracts containing ellagitannins and their use |
| 03/11/2009 | EP2032987A2 Pharmacological treatment of cognitive impairment |
| 03/11/2009 | EP2032701A1 Polynucleotides and polypeptide sequences involved in cancer |
| 03/11/2009 | EP2032699A2 Inhibitors of hcap18/ll-37 for use in the treatment of breast cancer |
| 03/11/2009 | EP2032594A1 Glycyrrhetinic acid derivatives |
| 03/11/2009 | EP2032593A1 Amino derivatives of b-homoandrostanes and b-heteroandrostanes |
| 03/11/2009 | EP2032591A2 Glucan compositions and methods of enhancing cr3 dependent neutrophil-mediated cytotoxicity |
| 03/11/2009 | EP2032585A2 Substituted pteridines as therapeutic agents |
| 03/11/2009 | EP2032584A2 Thiadiazole compounds and methods of use thereof |
| 03/11/2009 | EP2032583A1 New chemical compounds |
| 03/11/2009 | EP2032582A1 Pyrimidine derivatives as pi3k inhibitors |
| 03/11/2009 | EP2032581A2 Polymorphic forms and process |
| 03/11/2009 | EP2032578A2 Triazolopyridazine derivatives |
| 03/11/2009 | EP2032575A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use |
| 03/11/2009 | EP2032574A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use |
| 03/11/2009 | EP2032573A1 Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| 03/11/2009 | EP2032572A1 Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them |
| 03/11/2009 | EP2032571A1 3 -amino-imidazo[1, 2-a]pyridine derivatives as sglt inhibitors |
| 03/11/2009 | EP2032570A1 Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 03/11/2009 | EP2032568A2 Polycyclic heterocyclic compounds and their use as modulators of the metabotropic glutamate 5 receptor |
| 03/11/2009 | EP2032567A1 Substituted heterocycles and use thereof |
| 03/11/2009 | EP2032566A1 Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 03/11/2009 | EP2032565A2 Benzisoxazole oxazolidinones as antibacterial agents |
| 03/11/2009 | EP2032564A2 Substituted benzimidazole thiophene benzyl ether compounds |
| 03/11/2009 | EP2032563A2 Benzimidazol substituted thiophene derivatives with activity on plk |
| 03/11/2009 | EP2032562A2 Selective inhibitors of rock protein kinase and uses thereof |
| 03/11/2009 | EP2032561A2 Dual molecules containing a peroxide derivative, their synthesis and therapeutic uses |
| 03/11/2009 | EP2032560A1 Substituted bicyclic and tricyclic thrombin receptor antagonists |
| 03/11/2009 | EP2032559A1 2-heterocycloamino-4-imidazolylpyrimidines as agents for the inhibition of cell proliferation |
| 03/11/2009 | EP2032558A1 Benzazepine derivatives as monoamine reuptake inhibitors |
| 03/11/2009 | EP2032555A1 Pyrrole derivatives with crth2 receptor modulator activity |
| 03/11/2009 | EP2032554A1 Piperidinyl pyrimidine derivatives |
| 03/11/2009 | EP2032546A1 Oxazole derivatives and their use in the treatment of diabetes and obesity |
| 03/11/2009 | EP2032544A1 Crystalline forms of letrozole and processes for making them |
| 03/11/2009 | EP2032543A1 2-anilino-4-aminoalkyleneaminopyrimidines |
| 03/11/2009 | EP2032542A2 Heterocyclic aspartyl protease inhibitors |
| 03/11/2009 | EP2032539A2 Benzazepinones as sodium channel blockers |
| 03/11/2009 | EP2032536A2 Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
| 03/11/2009 | EP2032535A1 Spirocyclic nitriles as protease inhibitors |
| 03/11/2009 | EP2032534A1 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions |
| 03/11/2009 | EP2032531A1 Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide |
| 03/11/2009 | EP2032530A1 Pyrrolidine compounds as renin inhibitors |
| 03/11/2009 | EP2032525A1 Deuterated aminoglycidyl compounds |
| 03/11/2009 | EP2032180A2 Glucan preparations |
| 03/11/2009 | EP2032170A1 Anti-inflammatory composition comprising glycine and lactoferrin and the use thereof |
| 03/11/2009 | EP2032153A1 Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma |
| 03/11/2009 | EP2032148A2 Composition containing lactobacillus sp. and a cannabinoid receptor and/or a opioid receptor agonist |
| 03/11/2009 | EP2032145A2 Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use |
| 03/11/2009 | EP2032144A2 Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
| 03/11/2009 | EP2032143A1 Treating cancer with cardiac glycosides |
| 03/11/2009 | EP2032142A2 Novel compounds |
| 03/11/2009 | EP2032141A1 Inhibitors of janus kinases |
| 03/11/2009 | EP2032140A1 Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp) |
| 03/11/2009 | EP2032139A2 Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone |
| 03/11/2009 | EP2032138A2 Aminothiazole derivatives as inhibitors of mark |
| 03/11/2009 | EP2032137A2 Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
| 03/11/2009 | EP2032136A1 Compositions and kits comprising a melatonin component and a chondroprotective component |
| 03/11/2009 | EP2032135A2 Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist |
| 03/11/2009 | EP2032134A2 Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis |
| 03/11/2009 | EP2032133A2 Compositions and kits comprising a melatonin component and an omega-3-fatty acid component |
| 03/11/2009 | EP2032132A2 Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury |
| 03/11/2009 | EP2032131A2 Method of treatment |
| 03/11/2009 | EP2032130A2 Ophthalmic compositions for treating ocular hypertension |
| 03/11/2009 | EP2032129A2 Compositions of phenylephrine useful for treatment of respiratory illness |
| 03/11/2009 | EP2032128A1 Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain |
| 03/11/2009 | EP2032126A2 Rabeprazole formulation |
| 03/11/2009 | EP2032125A2 Ropinirole-containing pharmaceutical compositions in the form of a gel, uses thereof |
| 03/11/2009 | EP2032123A1 Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders |
| 03/11/2009 | EP2031965A2 Novel compounds |
| 03/11/2009 | EP2031964A2 Treating obesity with muscarinic receptor m1 antagonists |
| 03/11/2009 | EP1940782B1 N-phenyl phenylacetamide non-nucleoside reverse transcriptase inhibitors |
| 03/11/2009 | EP1934207B1 Substituted 4-phenyl piperidines for use as renin inhibitors |
| 03/11/2009 | EP1919475B1 Tetrahydro- beta-carbolin-sulfonamide derivatives as 5-ht6 ligands |
| 03/11/2009 | EP1888027B1 Medicated product for local use based on natural materials |
| 03/11/2009 | EP1879580B1 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility |
| 03/11/2009 | EP1874410B1 Depigmenting or brightening cosmetic composition comprising at least one oxazolin as an active ingredient |
| 03/11/2009 | EP1863767B1 Metabolites for nk-i antagonists for emesis |
| 03/11/2009 | EP1835902B1 Spiro[bornyl-2,4'-(1,3-dioxanes)] and their uses as fragrance ingredients |
| 03/11/2009 | EP1819710B1 New pyridothienopyrimidine derivatives |
| 03/11/2009 | EP1819332B1 Pyrrolopyridine-2-carboxylic acid amides |
| 03/11/2009 | EP1814877B1 Diphenyl substituted alkanes as flap inhibitors |
| 03/11/2009 | EP1789416B1 Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents |
| 03/11/2009 | EP1786400B1 Pharmaceutical compositions for controlled release delivery of biologically active compounds |
| 03/11/2009 | EP1763368B1 Combinations comprising antimuscarinic agents and beta-adrenergic agonists |
| 03/11/2009 | EP1753758B1 Mercaptoimidazoles as ccr2 receptor antagonists |
| 03/11/2009 | EP1737488B1 Treatment of fungal infections |
| 03/11/2009 | EP1715878B1 Use of the lupinoside pa4 or a butanol fraction of an extract of pueraria tuberosa for the treatment of diabetes type 2 |
| 03/11/2009 | EP1696937B1 Prebiotic combination products |
| 03/11/2009 | EP1667770B1 Method for the production of derivatives of 4a,5,9,10,11,12-hexahydrobenzofuro [3a,3,2][ 2]- benzazepine |
| 03/11/2009 | EP1656374B1 Thiazole derivatives as npy antagonists |
| 03/11/2009 | EP1656129A4 Blockade of mtor to prevent a hormonal adaptive response |
| 03/11/2009 | EP1641463B1 Compositions in the form of a spray comprising a pharmaceutical agent at least one volatile silicone and a non-volatile oily phase |
| 03/11/2009 | EP1631574B1 Colchicoside analogues |
| 03/11/2009 | EP1611111B1 Process for resolving 2,4-diamino-3,6-dihydro-1,3,5-triazines, useful for the treatment of disorders associated with insulin resistance syndrome |
| 03/11/2009 | EP1590324B1 NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVES AS INHIBITORS OF PHOSPHOLIPASE A sb 2 /sb |
| 03/11/2009 | EP1587553B1 Quaternary ammonium esters for disinfection and preservation |